Physician profile
Sonia Valle
NPI 1114908340
$4,788.74
in general payments reported to CMS, 2019-2025
26 companies · $1,408 in 2025
The $1,408 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $194 · 2021: $316 · 2022: $345 · 2023: $566 · 2024: $1,547 · 2025: $1,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,521.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $791.16 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $647.89 | 2019-2025 | Tryptyr, Precision7, Precision 1 |
| Biotissue Holdings INC. | $470.50 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $407.03 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $387.23 | 2023-2025 | Cequa |
| Glaukos Corporation | $261.28 | 2024-2025 | Idosetr, Photrexa |
| Dompe US, INC. | $245.05 | 2024-2025 | Oxervate |
| Amgen INC. | $201.17 | 2024 | Tepezza |
| Lumenis Be INC | $148.52 | 2022 | |
| Harrow Eye, LLC | $131.46 | 2025 | Vevye |
| Coopervision INC. | $119.36 | 2021-2025 | Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $106.27 | 2019 | |
| Oyster Point Pharma, INC. | $104.85 | 2022-2024 | Tyrvaya |
| Lombart Brothers, INC. | $98.20 | 2025 | Opd-III |
| Kala Pharmaceuticals, INC. | $90.16 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $77.17 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $73.32 | 2019 | |
| Sight Sciences, INC. | $72.48 | 2019 | |
| Asd Specialty Healthcare, LLC | $62.16 | 2020 | |
| Maculogix, INC. | $58.25 | 2019 | |
| Genzyme Corporation | $55.85 | 2020 | |
| Allergan, INC. | $50.16 | 2021 | |
| Visioneering Technologies, INC. | $46.23 | 2019-2020 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Astellas Pharma US INC | $28.00 | 2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $16.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Valle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.